Kanavos P - Search Results

1

Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.

Visintin E, Tinelli M, Kanavos P. Visintin E, et al. Among authors: kanavos p. Health Policy. 2019 Feb;123(2):118-129. doi: 10.1016/j.healthpol.2018.08.019. Epub 2018 Sep 6. Health Policy. 2019. PMID: 30227974 Review.

2

Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.

Vandergrift M, Kanavos P. Vandergrift M, et al. Among authors: kanavos p. Health Policy. 1997 Sep;41(3):241-60. doi: 10.1016/s0168-8510(97)00036-5. Health Policy. 1997. PMID: 10170092

3

Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain.

Lluch M, Kanavos P. Lluch M, et al. Among authors: kanavos p. Health Policy. 2010 May;95(2-3):245-54. doi: 10.1016/j.healthpol.2009.11.002. Epub 2010 Jan 6. Health Policy. 2010. PMID: 20056292

4

Medical technology procurement in Europe: a cross-country comparison of current practice and policy.

Sorenson C, Kanavos P. Sorenson C, et al. Among authors: kanavos p. Health Policy. 2011 Apr;100(1):43-50. doi: 10.1016/j.healthpol.2010.08.001. Epub 2010 Sep 16. Health Policy. 2011. PMID: 20846739

5

Determinants of branded prescription medicine prices in OECD countries.

Kanavos PG, Vandoros S. Kanavos PG, et al. Health Econ Policy Law. 2011 Jul;6(3):337-67. doi: 10.1017/S1744133111000090. Health Econ Policy Law. 2011. PMID: 21676345 Free article.

6

Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions.

Nicod E, Kanavos P. Nicod E, et al. Among authors: kanavos p. Health Policy. 2012 Dec;108(2-3):167-77. doi: 10.1016/j.healthpol.2012.09.012. Epub 2012 Oct 22. Health Policy. 2012. PMID: 23088802

7

Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.

Kanavos P. Kanavos P. Health Policy. 2014 Nov;118(2):229-41. doi: 10.1016/j.healthpol.2014.08.005. Epub 2014 Aug 27. Health Policy. 2014. PMID: 25201433 Free article.

8

A comparative analysis of coverage decisions for outpatient pharmaceuticals: evidence from Denmark, Norway and Sweden.

Grepstad M, Kanavos P. Grepstad M, et al. Among authors: kanavos p. Health Policy. 2015 Feb;119(2):203-11. doi: 10.1016/j.healthpol.2014.12.013. Epub 2014 Dec 22. Health Policy. 2015. PMID: 25564278

9

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence.

Angelis A, Tordrup D, Kanavos P. Angelis A, et al. Among authors: kanavos p. Health Policy. 2015 Jul;119(7):964-79. doi: 10.1016/j.healthpol.2014.12.016. Epub 2014 Dec 30. Health Policy. 2015. PMID: 25661982 Review.

10

Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study.

Nicod E, Kanavos P. Nicod E, et al. Among authors: kanavos p. Health Policy. 2016 Jan;120(1):35-45. doi: 10.1016/j.healthpol.2015.11.007. Epub 2015 Dec 4. Health Policy. 2016. PMID: 26723201 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters